Integer Holdings Corporation (ITGR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong sales in some areas but declines in others, particularly CRM&N. Financial health is stable with increased free cash flow, but guidance adjustments and margin declines raise concerns. The Q&A indicates management's confidence in long-term growth, though short-term challenges exist. Despite optimistic 2027 projections, the lack of detailed guidance and rounding adjustments suggest cautious sentiment, leading to a neutral rating.
Key Financial Performance
Full Year Sales Sales increased 8% on a reported basis and over 6% organically. Reasons for the increase include higher sales volume, improved profitability, and effective capital management.
Adjusted Operating Income Increased 13% year-over-year. This was driven by higher sales volume, manufacturing efficiencies, and disciplined expense management.
Adjusted EPS Increased 21% year-over-year. The increase reflects higher sales, improved profitability, and effective capital management.
Fourth Quarter Sales Totaled $472 million, reflecting 5% growth on a reported basis and 2% growth on an organic basis. Growth was driven by acquisitions, strategic exits, and foreign currency fluctuations.
Adjusted EBITDA (Fourth Quarter) $106 million, up 11% year-over-year. This was due to improved gross margins and operational efficiencies.
Adjusted Operating Margin (Fourth Quarter) Expanded by 74 basis points to 17.6%, driven by improvement in gross margin.
Adjusted Net Income (Fourth Quarter) $62 million, up 22% year-over-year. This reflects interest expense savings and operational improvements.
Adjusted EPS (Fourth Quarter) $1.76, up 23% year-over-year. The increase was due to interest expense savings and operational improvements.
Cardio & Vascular Sales (Fourth Quarter) Increased 11% to $284 million, driven by acquisitions and strong demand in neurovascular.
CRM&N Sales (Fourth Quarter) Decreased 2% to $167 million, primarily due to lower demand from select emerging customers with PMA products.
Free Cash Flow (Full Year) $105 million, an increase of $5 million year-over-year. This was driven by disciplined capital expenditures and operational cash flow management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
3 new products in electrophysiology and neuromodulation: Sales of these products are expected to be significantly lower in 2026 due to lower-than-expected market adoption, causing a 3%-4% headwind to organic sales.
Product development sales: Increased by over 300% since 2017, with 80% focused on high-growth markets, indicating a strong development pipeline.
Cardio & Vascular market: Sales increased 11% in Q4 2025, driven by acquisitions and strong demand in neurovascular. Trailing 4-quarter sales grew 17%.
CRM&N market: Sales decreased 2% in Q4 2025 due to lower demand from select emerging customers. Trailing 4-quarter sales increased 1%.
Adjusted operating income: Increased 13% in 2025, with a margin expansion of 76 basis points to 17.3%, driven by gross margin improvement and disciplined expense management.
ERP modernization program: A multiyear initiative to enhance operational capabilities, improve productivity, and support scalable growth.
Share repurchase program: Repurchased $60 million in Q4 2025 and announced a $50 million accelerated share repurchase program, reflecting confidence in strategy and financial position.
Tuck-in acquisitions: Enhanced capabilities in high-growth markets, including neurovascular and micro machining, and supported vertical integration strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Adoption of New Products: The company faces a 3% to 4% headwind in 2026 due to lower-than-expected market adoption of three new products, two in electrophysiology and one in neuromodulation. These products represented nearly 6% of total sales in 2025, and their underperformance is expected to significantly impact sales.
Neuromodulation Demand: Decline in neuromodulation sales, primarily driven by lower demand from select emerging customers with PMA products, is affecting the company's performance.
Temporary Headwinds in 2026: The company anticipates temporary headwinds in 2026, including reduced sales from three new products and lower manufacturing volumes, which are expected to impact adjusted operating income and EPS.
Supply Chain and Operational Challenges: The company is undergoing a multiyear ERP modernization program to enhance operational capabilities, improve productivity, and manage working capital. This initiative may pose risks related to implementation challenges and disruptions.
Economic and Market Pressures: The company expects flat to low single-digit growth in key product lines due to market pressures and economic uncertainties, which could impact overall financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Outlook: Reported sales are expected to range from $1.826 billion to $1.876 billion, representing a change of -1% to +1%. Organic sales are projected to be flat to up 3%. Adjusted operating income is expected to range from $304 million to $324 million, reflecting a change of -5% to +1%. Adjusted EPS is projected to range from $6.29 to $6.78, representing a change of -2% to +6%. Cash flow from operations is expected to be between $200 million and $220 million, with capital expenditures of $95 million to $105 million, resulting in free cash flow of $100 million to $120 million.
2026 Sales Performance: Sales are expected to be impacted by lower sales of three new products, resulting in a 3% to 4% headwind. Excluding these products, underlying sales are expected to grow 4% to 6%, in line with the market. Organic sales are expected to decline in the first half of 2026 and return to market growth in the second half.
2027 Growth Expectations: The company expects to return to 200 basis points above-market organic growth in 2027, supported by a robust and diversified pipeline and the strength of the underlying business.
Capital Management and Investments: The company plans to continue investing in growth initiatives, including capital expenditures of approximately 5% to 6% of sales and tuck-in acquisitions. A $50 million accelerated share repurchase program has been announced, reflecting confidence in the company's strategy and financial position.
Market Focus and Strategic Initiatives: The company is focused on high-growth markets such as electrophysiology, neurovascular, structural heart, and neuromodulation. Investments in advanced manufacturing, automation, and capacity expansion are expected to support long-term growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase in Q4 2025: In the fourth quarter, Integer repurchased $60 million of its common stock.
Accelerated Share Repurchase Program: Integer announced its intention to initiate an accelerated share repurchase program to repurchase approximately $50 million under its existing share repurchase authorization.
Share Repurchase Program Authorization: In November, the Board authorized a share repurchase program of up to $200 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was the high end of the preliminary range for organic growth guidance lowered from 0%-4% to 0%-3%?
A:The adjustment was not due to specific dynamics in January or other factors but was more of a rounding decision.
Q:What drives the return to operating income growth above sales growth in 2027?
A:The company expects to achieve above-market growth in 2027, with a return to 200 basis points over market performance and continued margin expansion as part of their long-term strategy and Integral Production system.
Q:What is the expected contribution from new PMA products this year and their long-term outlook?
A:The company expects the portfolio of PMA products to grow 15%-20% over a 3- to 5-year period. They have good visibility into the launch dates and expected revenues, which are risk-adjusted to provide confidence in this growth projection.
Q:Why was the organic growth guidance reduced by 100 basis points, and does it reflect changes in customer forecasts?
A:The reduction does not reflect changes in customer forecasts. The guidance is aligned with expectations and prior communication, with the adjustment attributed to rounding.
Q:Why did DSOs increase meaningfully at the end of Q4?
A:The company limited accounts receivable factoring in Q4 to maintain financial flexibility, which raised DSOs.
Q:Why is there a steep year-over-year decline in Q1 operating margin despite extra selling days?
A:The decline is due to fixed costs being harder to absorb on lower sales numbers in Q1. As sales grow throughout the year, operating margin rates are expected to improve.
Q:What is the visibility into customer forecasts and their alignment with the company's guidance?
A:Customer discussions and forecasts are in full alignment with the company's guidance, which was modeled with a balanced view of potential outcomes.
Q:What is the organic Q1 to Q2 revenue bridge, and how do one-time impacts affect recovery?
A:The company expects Q1 to be flat to down low single digits, with a 5% tailwind in Q1 and a 5% headwind in Q4. The quarterly profiling aligns with expectations of starting the year lower and growing to market growth throughout 2026.
Q:How does the new CEO view shareholder value creation in the short and long term?
A:The CEO believes in a long-term strategy to deliver value to customers, which in turn creates sustainable shareholder value. The focus is on refining and executing the company's strategy.
Q:What drives the trajectory to above-market growth in 2027?
A:The core business is strong and expected to grow in alignment with the market. New product launches in the second half of 2026 and during 2027, along with the absence of headwinds from three specific products, contribute to the confidence in achieving above-market growth.
Q:What is the 15%-20% growth goal for PMA products, and how does the company address challenges with specific products?
A:The company expects PMA products to grow 15%-20% over 3-5 years. Despite challenges with one product, the overall portfolio is expected to grow in alignment with the market.
Q:Why would 2027 growth not exceed 200 basis points above market?
A:The company’s long-term strategic objective is to grow 200 basis points above market. Specific guidance for 2027 will be provided next year.
Q:Does the end market table reflect the entire market or just areas where the company is exposed?
A:The table reflects the broad end market, not just the areas where the company is exposed.
Q:What has changed internally since Q3 in terms of running the business and setting goals?
A:The company has not made changes to its strategy or operations. It continues to focus on delivering value to customers and shareholders, despite short-term headwinds from three new products.
Q:Why is the company unable to absorb fixed costs in Q1, and how does it manage production changes with customers?
A:Fixed costs are harder to absorb due to lower sales in Q1. The company works closely with customers to manage production changes collaboratively, avoiding inefficiencies and ensuring smooth ramp-ups or ramp-downs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact reasons for the reduction in the high end of the guidance range, attributing it to rounding. They also did not provide granular details on the discrete products impacting margins or the exact contributions of new PMA products in 2025.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cardiac Rhythm
Integer
RD
addition
automation
benefit
capability product
chain
culture
customer success
design
development sale
device
end outlook
example
expertise capability
facility
income margin
industry
laser
life
market customer
market decline
micro machining
neuromodulation market
outlook sale
portfolio
processing
product development
product headwind
product market
quality
repurchase program
saving
share repurchase
system
team
value creation
ITGR Transcript
Integer Holdings Corporation (ITGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Integer Holdings Corporation (ITGR) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates strong financial performance with significant revenue, gross margin, operating income, and net income growth. Despite supply chain and regulatory challenges, the company shows resilience and effective cost management. The absence of strategic initiatives and return discussions is offset by the robust financial health, which suggests a positive market reaction. Given the market cap of approximately $3.8 billion, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
Integer Holdings Corporation (ITGR) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call reveals mixed signals: strong sales in some areas but declines in others, particularly CRM&N. Financial health is stable with increased free cash flow, but guidance adjustments and margin declines raise concerns. The Q&A indicates management's confidence in long-term growth, though short-term challenges exist. Despite optimistic 2027 projections, the lack of detailed guidance and rounding adjustments suggest cautious sentiment, leading to a neutral rating.
Integer Holdings Corporation (ITGR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
ITGR Slides
ITGR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
